Application of mRNA for use as a therapeutic against tumour diseases
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
A61K-039/00
A61K-038/19
A61K-009/00
A61K-048/00
출원번호
US-0965613
(2015-12-10)
등록번호
US-9655955
(2017-05-23)
우선권정보
DE-101 62 480 (2001-12-19)
발명자
/ 주소
Hoerr, Ingmar
Von Der Mülbe, Florian
Pascolo, Steve
출원인 / 주소
CureVac AG
대리인 / 주소
Parker Highlander PLLC
인용정보
피인용 횟수 :
2인용 특허 :
43
초록▼
The present invention relates to a pharmaceutical composition comprising at least one mRNA comprising at least one coding region for at least one antigen from a tumor, in combination with an aqueous solvent and preferably a cytokine, e.g. GM-CSF, and a process for the preparation of the pharmaceutic
The present invention relates to a pharmaceutical composition comprising at least one mRNA comprising at least one coding region for at least one antigen from a tumor, in combination with an aqueous solvent and preferably a cytokine, e.g. GM-CSF, and a process for the preparation of the pharmaceutical composition. The pharmaceutical composition according to the invention is used in particular for therapy and/or prophylaxis against cancer.
대표청구항▼
1. A method of stimulating an antitumor immune response in a subject comprising administering an effective amount of a cell-free composition comprising mRNA encoding an GP100 antigen to a subject in need thereof, thereby stimulating a T-cell mediated cytotoxic anticancer immune response in the subje
1. A method of stimulating an antitumor immune response in a subject comprising administering an effective amount of a cell-free composition comprising mRNA encoding an GP100 antigen to a subject in need thereof, thereby stimulating a T-cell mediated cytotoxic anticancer immune response in the subject. 2. The method of claim 1, wherein the subject has a cancer. 3. The method of claim 2, wherein the cancer is a skin cancer. 4. The method of claim 1, wherein the composition comprises mRNA encoding at least 2, 3, 4 or 5 different tumor antigens. 5. The method of claim 1, wherein the method further comprises administering at least 2, 3, 4 or 5 different cell-free compositions comprising mRNA encoding different tumor antigens to the subject. 6. The method of claim 1, wherein the mRNA is complexed with as least one cationic or polycationic agent. 7. The method of claim 6, wherein the cationic or polycationic agent is chosen from the group consisting of protamine, poly-L-lysine, poly-L-arginine and histones. 8. The method of claim 7, wherein the mRNA is complexed with protamine. 9. The method of claim 1, further comprising administering one or more adjuvant(s) to the subject. 10. The method of claim 9, wherein the adjuvant is chosen from the group consisting of lipopolysaccharide, TNF-α, CD40 ligand, GP96, oligonucleotides with a CpG motif, aluminum hydroxide, Freund's adjuvant, a lipopeptide and a cytokine. 11. The method of claim 10, wherein the cytokine is GM-CSF. 12. The method of claim 1, wherein the mRNA encoding the antigen has a different nucleic acid sequence compared with the wild-type mRNA encoding the antigen. 13. The method of claim 1, wherein the mRNA comprises a 5′ cap structure, at least one IRES and/or a poly(A+) tail of at least 25 nucleotides. 14. The method of claim 13, wherein the mRNA comprises a 5′ cap structure and a poly(A+) tail of at least 25 nucleotides. 15. The method of claim 1, wherein the mRNA comprises at least one 5′-stabilizing sequence and/or at least one 3′-stabilizing sequence. 16. The method of claim 15, wherein the 5′- and/or the 3′-stabilizing sequence(s) is/are chosen from the group consisting of untranslated sequences (UTR) of the β-globin gene and a stabilizing sequence of the general formula (C/U)CCANxCCC(U/A)PyxUC(C/U)CC. 17. The method of claim 1, wherein the mRNA comprises at least one analog of naturally occurring nucleotide selected from the group consisting of phoshorothioates, phosphoroamidates, peptide nucleotides, methylphosphates, 7-deazaguanosine, 5-methylcytosine and inosine. 18. The method of claim 1, wherein the cell-free composition comprising mRNA is administered by injection of an aqueous solution comprising the mRNA. 19. The method of claim 1, wherein the cell-free composition comprising mRNA is administered intradermally. 20. The method of claim 1, wherein the cell-free composition comprising mRNA is administered two or more times.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (43)
Hoerr, Ingmar; Von Der Mulbe, Florian; Pascolo, Steve, Application of mRNA for use as a therapeutic against tumour diseases.
Andrus William A. (San Francisco CA) McCollum Christie D. (Foster City CA) Zon Gerald (San Carlos CA), Automated system for polynucleotide synthesis and purification.
Andrus William A. (San Francisco CA) McCollum Christie D. (Foster City CA) Zon Gerald (San Carlos CA), Automated system for polynucleotide synthesis and purification.
Mark David F. (Danville CA) Lin Leo S. (Fremont CA) Yu Lu Shi-da (Oakland CA) Wang Alice M. (Walnut Creek CA), Cysteine-depleted muteins of biologically active proteins.
Felgner Philip L. (Rancho Santa Fe CA) Wolff Jon A. (Madison WI) Rhodes Gary H. (Leucadia CA) Malone Robert W. (Chicago IL) Carson Dennis A. (Del Mar CA), Delivery of exogenous DNA sequences in a mammal.
Raz, Eyal; Kornbluth, Richard; Catanzaro, Antonio; Hayashi, Tomoko; Carson, Dennis, Immunomodulatory polynucleotides in treatment of an infection by an intracellular pathogen.
Felgner Philip L. ; Wolff Jon Asher ; Rhodes Gary H. ; Malone Robert Wallace ; Carson Dennis A., Induction of a protective immune response in a mammal by injecting a DNA sequence.
Horton,Holly; Parker,Suezanne; Manthorpe,Marston; Felgner,Philip L.; Hartikka,Jukka, Methods for treating cancer using cytokine-expressing polynucleotides.
Agrawal,Sudhir; Kandimalla,Ekambar R.; Yu,Dong; Bhagat,Lakshmi, Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5' ends.
Monforte Joseph Albert (Berkeley CA) Becker Christopher Hank (Menlo Park CA) Shaler Thomas Andrew (San Francisco CA) Pollart Daniel Joseph (Menlo Park CA), Oligonucleotide sizing using immobilized cleavable primers.
Koths Kirston E. (El Cerrito CA) Halenbeck Robert F. (San Rafael CA) Mark David F. (Plainsboro NJ) Nitecti Danutee (Berkeley CA), Oxidation-resistant muteins of Il-2 and other protein.
Pamela Hawley-Nelson ; Jianqing Lan ; PoJen Shih ; Joel A. Jessee ; Kevin P. Schifferli ; Gulilat Gebeyehu ; Valentina C. Ciccarone ; Krista L. Evans, Peptide-enhanced transfections.
Wagner,Hermann; Lipford,Grayson; Heeg,Klaus, Pharmaceutical compositions comprising a polynucleotide and optionally an antigen especially for vaccination.
Cabilly Shmuel (Monrovia CA) Heyneker Herbert L. (Burlingame CA) Holmes William E. (Pacifica CA) Riggs Arthur D. (La Verne CA) Wetzel Ronald B. (San Francisco CA), Recombinant immunoglobin preparations.
Mark David F. (Hercules CA) Lin Leo S. (Fremont CA) Yu Lu Shi-Da (Oakland CA), Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-
상세보기
Chong Kong-Teck (Union City CA), Treatment of infections with lymphokines.
Derosa, Frank; Smith, Lianne; Heartlein, Michael; Guild, Braydon Charles, Synergistic enhancement of the delivery of nucleic acids via blended formulations.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.